The MarketWatch News Department was not involved in the creation of this content. HINGHAM, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and manufacturer of ...

Microbot Medical Inc. MBOT recently received FDA 510(k) clearance for its LIBERTY Endovascular Robotic System, marking a major regulatory milestone for the company. The LIBERTY system is designed to ...

HINGHAM, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and manufacturer of the innovative LIBERTY ® Endovascular Robotic System, announces that its Chief ...

$25.2 million in first closing and $4 million in second closing, with up to an additional approximately $63 million of potential aggregate gross proceeds upon the exercise in full of short-term ...

Limited Market Release (LMR) of the LIBERTY ® System is on Schedule Building on Positive Customer Feedback and Growing Market Enthusiasm, the Company Prepares for Full Market Release (FMR) in Q2 ...

Microbot Medical has secured a non-dilutive NIS2.15m (around $630,000) grant from the Israel Innovation Authority (IIA) to bolster its manufacturing capabilities, as well as progress towards the ...

Microbot Medical Inc. company and executive profile by Barron's. View the latest MBOT company infomation and executive bios.

HINGHAM, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (MBOT), developer and manufacturer of the innovative LIBERTY ® Endovascular Robotic System, today announced that Harel Gadot, ...

HINGHAM, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (MBOT) (“Microbot” or the “Company”), today announced the third and final closing of its previously announced exercise of ...